EUTECNIQAtlas

Every page of EUTECNIQ on one mapArrow keys move through results · Enter opens · Esc closes

Supplements A–Z Botanical Sources: 9

Velvet bean (Mucuna) Mucuna pruriens (L.) DC.

Also called: velvet bean, Mucuna pruriens, Dolichos pruriens (basionym), Stizolobium pruriens (synonym)

Mucuna pruriens is a tropical legume whose seeds naturally contain levodopa, the dopamine precursor used as a prescription Parkinson's disease medicine. Seed powder has a long history in Ayurvedic medicine; several recent trials used powder from roasted seeds.

Category
Botanical
Part used
Seed (several recent trials used powder from roasted seeds)
Strongest evidence
C Limited
Native range
Native to the tropical and subtropical Old World (POWO: "Tropical & Subtropical Old World")
Reviewed
2026-10-29

Class 2 Moderately studied in people. This entry cites 4 RCTs of Mucuna pruriens seed powder alone versus levodopa preparations (sources [2], [3], [4], [7]), 8 to 32 people with Parkinson's disease. [2]

Fact-checked 2026-10-29 · How this guide is made

Education, not medical advice. These statements have not been evaluated by the Food and Drug Administration. This information is not intended to diagnose, treat, cure or prevent any disease, or to replace any medication or medical advice. EUTECNIQ sells no supplements today, and this page links to no product. Supplements can interact with medicines; ask a doctor or pharmacist before use, especially in pregnancy, while breastfeeding, before surgery or for a child.

Evidence

What research has studied

Grades describe the human evidence in the cited sources, not a recommendation. A means consistent randomized trials; X means good trials found no effect.

4 topics studied1 body area · strongest grade C

A consistent trialsB some positive trialsC limited human evidenceD lab or animal onlyX no effect in good trials

From the table below Each topic in the table is placed on the part of the body it names, colored by its strongest grade. Tap an area, or open a line in the list, to see its topics. The map shows what was studied, not what Velvet bean (Mucuna) does: a C or X area is not evidence of benefit. All 1,071 findings on one body map.
Topics studied for Velvet bean (Mucuna), evidence grade and finding
Topic studiedGradeWhat the evidence shows
Motor symptoms in Parkinson's disease (single doses)CIn a double-blind crossover trial (18 patients with advanced Parkinson's disease), single doses of roasted-seed powder met noninferiority criteria versus levodopa/benserazide for motor response, with fewer dyskinesias. [2]
Levodopa response compared with standard levodopa/carbidopaCIn a double-blind crossover trial in 8 patients, a 30 g single dose gave faster onset (34.6 vs 68.5 minutes) and longer on-time than 200/50 mg levodopa/carbidopa, without more dyskinesia. [3]
Daily use over 16 weeks in advanced Parkinson's diseaseCIn a 16-week randomized crossover pilot (14 patients), 7 stopped mucuna early because of gastrointestinal side effects or worsening motor performance; in those who tolerated it, response was similar to levodopa/carbidopa. [4]
12-month use in untreated Parkinson's diseaseCAn open-label randomized phase 2 trial (32 untreated patients in sub-Saharan Africa) reported quality-of-life, motor and non-motor outcomes similar to standard levodopa plus a decarboxylase inhibitor over 12 months. [7]

Main constituents: Levodopa (L-dopa), a dopamine precursor; the plant is described as naturally rich in levodopa [1]

Amounts

Amounts studied and limits

Amounts used in research, not dosing advice. Products differ in form and strength; a clinician can advise on an individual dose.

  • Single doses of 12.5 mg/kg and 17.5 mg/kg of roasted-seed powder in an 18-patient crossover trial. [2]
  • Single doses of 15 g and 30 g of a mucuna seed preparation in an 8-patient crossover trial. [3]

No official upper intake level has been set.

Safety

Safety and side effects

  • Liver (NIH LiverTox)
    Nothing found

    No published information found in the sources checked.

    Details and sources
  • Pregnancy and breastfeeding
    Nothing found

    No published information found in the sources checked.

    Details and sources
  • Interactions with medicines
    Nothing found

    No published information found in the sources checked.

    Details and sources
  • Cancer evaluations (IARC, NTP)
    None found

    No IARC or NTP evaluation was found in the lists checked.

    Details and sources
  • FDA new dietary ingredient notifications
    None on FDA's list

    FDA does not approve dietary supplements. Each entry is one party's filing.

    Details and sources
  • Dose in official monographs
    None found

    No published information found in the sources checked.

    Details and sources
  • Despite its natural origin, mucuna is a potent dopaminergic therapy requiring the same caution as commercial levodopa medicines; overuse and unsupervised self-medication have been associated with dyskinesia, dopamine dysregulation syndrome and psychiatric complications. [1]
  • Cases of toxicity from improper seed preparation have been reported. [1]
  • A 58-year-old woman who ate 5 raw seeds developed nausea, vomiting and diarrhea, followed by confusion, hallucinations and amnesia. [5]
  • A 1990 report in The Lancet described an outbreak of acute toxic psychosis attributed to Mucuna pruriens. [6]
  • The plant is often involved in cases of intense itching after contact with the hairs that grow on its beans. [5]
  • In a 12-month trial, adverse events were more frequent with mucuna than standard levodopa (56% vs 37.5%; not statistically significant); most were mild. Long-term safety data are scarce. [7]
  • Two Parkinson's disease specialists advise that mucuna use should remain restricted to clinical trials or neurologist-led protocols until more robust evidence of long-term safety and efficacy emerges. [1]
Regulation

Regulatory status

  • US: FDA states that under DSHEA it does not have the authority to approve dietary supplements before they are marketed; firms are responsible for ensuring their products are not adulterated or misbranded. [9]
Profile

Safety, quality and supply profile

Fourteen questions a careful buyer, formulator or clinician would ask, each answered only from a cited source (checked 2026-10-29). If our sources do not answer a question, we say so.

Compounds responsible

Compounds the sources name as the main or characteristic actives.

  • Levodopa (L-dopa) Dopamine precursor [P1]

US status

What FDA's published records show. FDA does not approve dietary supplements.

  • No NDI notification naming Mucuna pruriens (velvet bean) was found in FDA's published NDI list (dated July 9, 2026; checked 2026-10-29). FDA keeps no authoritative list of ingredients marketed before October 15, 1994. [P2]

Cancer evaluations (IARC and NTP)

Evaluations name the exact material tested, which may differ from a supplement.

  • No IARC or NTP carcinogenicity evaluation of Mucuna pruriens was found (IARC Monographs list of classifications and NTP technical reports checked 2026-10-29). [P3]

Liver (NIH LiverTox)

  • No published information found in the sources checked.

Interactions with medicines

  • No published information found in the sources checked.

Alcohol

  • No published information found in the sources checked.

Interactions with other herbs and supplements

  • No published information found in the sources checked.

Adulteration and substitution

  • No published information found in the sources checked.

What a certificate of analysis should cover

Tests a quality specification for this material would include, with the reason for each.

  • Identity test or examination of the dietary ingredient — 21 CFR 111.75(a)(1)(i) requires at least one appropriate test or examination to verify the identity of any component that is a dietary ingredient, unless FDA grants an exemption petition under 111.75(a)(1)(ii). [P4]

Supply and conservation

  • No published information found in the sources checked.

Absorption in people

  • In 8 Parkinson's patients, a single 30 g dose of a mucuna seed preparation gave peak plasma levodopa concentrations 110% higher and an area under the curve 165.3% larger than 200/50 mg levodopa/carbidopa, with a shorter time to peak. [P5]

Formulations studied to change absorption

Human data only.

  • No published information found in the sources checked.

Dose in official monographs

As the monograph states it, for its jurisdiction; not personal advice.

  • No published information found in the sources checked.

Pregnancy and breastfeeding

  • No published information found in the sources checked.

Sources for this profile

  1. Cilia R, Katzenschlager R. "To Bean or Not to Bean": Therein lie the hype and the hope. Advice to people with Parkinson in my clinic about Mucuna pruriens. J Parkinsons Dis 2026;16(4):788-794 (PMID 42053204), 2026-06. pubmed.ncbi.nlm.nih.gov
  2. FDA. Submitted 75-Day Premarket Notifications for New Dietary Ingredients (list dated July 9, 2026), 2026-07-09. fda.gov
  3. IARC Monographs. List of Classifications (list last updated 2026-07-23), 2026-07-23. monographs.iarc.who.int
  4. eCFR. 21 CFR 111.75 (up to date as of 10/23/2026), 2026-10-23. ecfr.gov
  5. Katzenschlager R, et al. Mucuna pruriens in Parkinson's disease: a double blind clinical and pharmacological study. J Neurol Neurosurg Psychiatry 2004;75(12):1672-7 (PMID 15548480), 2004-12. pubmed.ncbi.nlm.nih.gov
Sources

Sources

  1. Cilia R, Katzenschlager R. "To Bean or Not to Bean": Therein lie the hype and the hope. Advice to people with Parkinson in my clinic about Mucuna pruriens. J Parkinsons Dis 2026;16(4):788-794 (PMID 42053204), 2026-06. pubmed.ncbi.nlm.nih.gov
  2. Cilia R, et al. Mucuna pruriens in Parkinson disease: a double-blind, randomized, controlled, crossover study. Neurology 2017;89(5):432-438 (PMID 28679598), 2017-08-01. pubmed.ncbi.nlm.nih.gov
  3. Katzenschlager R, et al. Mucuna pruriens in Parkinson's disease: a double blind clinical and pharmacological study. J Neurol Neurosurg Psychiatry 2004;75(12):1672-7 (PMID 15548480), 2004-12. pubmed.ncbi.nlm.nih.gov
  4. Cilia R, et al. Daily intake of Mucuna pruriens in advanced Parkinson's disease: a 16-week, noninferiority, randomized, crossover, pilot study. Parkinsonism Relat Disord 2018;49:60-66 (PMID 29352722), 2018-04. pubmed.ncbi.nlm.nih.gov
  5. Maillot A, et al. Poisoning after ingestion of Mucuna pruriens seeds on Reunion Island. Wilderness Environ Med 2022;33(1):122-124 (PMID 34895813), 2022-03. pubmed.ncbi.nlm.nih.gov
  6. Infante ME, et al. Outbreak of acute toxic psychosis attributed to Mucuna pruriens. Lancet 1990;336(8723):1129 (PMID 1978001), 1990-11-03. pubmed.ncbi.nlm.nih.gov
  7. Cilia R, et al. Mucuna pruriens in untreated Parkinson's disease in sub-Saharan Africa: a 12-month, multicenter, randomized, controlled trial. J Parkinsons Dis 2026;16(1):99-109 (PMID 41269916), 2026-02. pubmed.ncbi.nlm.nih.gov
  8. Plants of the World Online (POWO), Royal Botanic Gardens, Kew. Mucuna pruriens (L.) DC. (accessed 2026-10-29). powo.science.kew.org
  9. U.S. Food and Drug Administration. Questions and Answers on Dietary Supplements (content current as of 08/27/2026), 2026-08-27. fda.gov
A
Consistent results from several randomized trials or a systematic review of them
B
Some positive randomized trials, but small, short, few or inconsistent
C
Limited human evidence: single small trials, observational data or mixed results
D
Laboratory or animal evidence only; not shown in people
X
Well-designed human trials found no meaningful effect

More in botanical: Aloe vera · American ginseng · Amla · Andrographis · Arjuna · Arnica · Aronia (black chokeberry) · Asafoetida · All entries A–Z · How to judge a supplement

Health information notice

These statements have not been evaluated by the Food and Drug Administration. Nothing on this site is intended to diagnose, treat, cure or prevent any disease. The information is for general education only. It is not medical advice and does not replace advice, diagnosis or treatment from a qualified health professional, or any medication a clinician has prescribed.

Do not start, stop or change any medicine, supplement or herbal product because of something you read here. Talk to your doctor or pharmacist first, especially if you are pregnant or breastfeeding, have a medical condition, take any medicines, are preparing for surgery, or are caring for a child. Research findings, traditional uses and safety data are reported as their sources state them; they are not recommendations or claims about any product. If you think you may have a medical emergency, call your doctor or 911 at once.

EUTECNIQ Sciences sells no supplements or health products today and receives nothing from any product or ingredient mentioned on this site; any commercial interest it later has in an ingredient will be stated on that ingredient’s page.

Ready to check what you take?

Free tools built on published reference values, each with its sources and its limits. Your lists stay in your browser.